Treatment by targeting microRNA: Miravirsen in patients with chronic HCV genotype 1 infection


The stability and propagation of hepatitis C virus ( HCV ) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 ( miR-122 ).
Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function.

In this phase 2a study at seven international sites, researchers have evaluated the safety and efficacy of Miravirsen in 36 patients with chronic HCV genotype 1 infection.
The patients were randomly assigned to receive five weekly subcutaneous injections of Miravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a 29-day period.
They were followed until 18 weeks after randomization.
Miravirsen resulted in a dose-dependent reduction in HCV RNA levels that endured beyond the end of active therapy. In the Miravirsen groups, the mean maximum reduction in HCV RNA level ( log10 IU per milliliter ) from baseline was 1.2 ( P=0.01 ) for patients receiving 3 mg per kilogram, 2.9 ( P=0.003 ) for those receiving 5 mg per kilogram, and 3.0 ( P=0.002 ) for those receiving 7 mg per kilogram, as compared with a reduction of 0.4 in the placebo group.

During 14 weeks of follow-up after treatment, HCV RNA was not detected in one patient in the 5-mg group and in four patients in the 7-mg group.

Investigators have observed no dose-limiting adverse events and no escape mutations in the miR-122 binding sites of the HCV genome.

In conclusion, the use of Miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance. ( Xagena )

Janssen HLA et al, N Engl J Med 2013; 368:1685-1694

XagenaMedicine_2013



Indietro

Altri articoli

Amyotrophic lateral sclerosis ( ALS ) is a rapidly progressing neurodegenerative disease that is characterized by motor neuron loss and...


Interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral Mongersen ( GED-0301...


Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon skipping allows synthesis...


Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes...


Crohn’s disease-related inflammation is characterized by defective activity of the immunosuppressive cytokine transforming growth factor ( TGF )-beta1, due to...


On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion,...


Dravet syndrome is a severe epilepsy syndrome characterized by infantile onset of therapy-resistant, fever-sensitive seizures followed by cognitive decline. Mutations...


A new type of treatment significantly reduces the severity of muscle weakness in myasthenia gravis, giving hope for a new...


Researchers have developed a successful strategy for interfering with Ebola virus infection that protected 75 percent of nonhuman primates exposed...